JNJ Soars on Record Earnings But Misses the Benchmark

Johnson & Johnson (JNJ) reported Q4 2025 earnings that exceeded expectations, with revenue rising 9.1% to $24.56 billion and net income hitting a 20-year high of $5.12 billion. The company maintained in-line guidance for 2026, with adjusted EPS and sales projections aligned with market forecasts.

Revenue

Johnson & Johnson’s Q4 revenue growth was driven by robust performance across its key segments. Innovative Medicine led with $15.76 billion in sales, reflecting strong demand for oncology and immunology therapies. The MedTech division contributed $8.80 billion, supported by advancements in cardiovascular and surgical technologies. Consolidated revenue reached $24.56 billion, marking a significant year-over-year increase.

Earnings/Net Income

The company’s EPS surged 49.0% to $2.12, while net income grew 49.1% to $5.12 billion, underscoring improved profitability. This performance highlights JNJ’s ability to leverage its portfolio and pipeline for sustained earnings growth.

Post-Earnings Price Action Review

A 30-day post-earnings strategy yielded a 7.55% return over three years, though it underperformed the benchmark’s 72.98% gain. The approach exhibited higher volatility, with a maximum drawdown of 22.06%, and a Sharpe ratio of 0.23, indicating stronger risk-adjusted returns than the benchmark.

CEO Commentary

CEO Joaquin Duato emphasized 2025 as a “catapult year,” driven by innovations in oncology, immunology, and neurology. He highlighted recent approvals like CAPLYTA and RYBREVANT FASPRO, alongside the Halda Therapeutics acquisition, as catalysts for long-term growth.

Guidance

For 2026, JNJ projected reported sales of $100.5 billion (6.7% midpoint growth) and adjusted EPS of $11.53 (6.9% midpoint growth). Guidance excludes GAAP measures due to legal uncertainties and acquisition impacts.

Additional News

1. M&A Activity: Johnson & Johnson acquired Halda Therapeutics to bolster its neuroscience pipeline.

2. Dividend Update: The company declared a $1.30 quarterly dividend (2.4% yield), reflecting confidence in its cash flow.

3. Legal Developments: A Maryland jury awarded $1.56 billion in a talc lawsuit, though JNJ plans to appeal the verdict.